Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease

EMBO Molecular Medicine

Volumn 4, Issue 4, 2012, Pages 344-352

  Kakuda, Nobuto ^a,b,c   Shoji, Mikio ^d   Arai, Hiroyuki ^e   Furukawa, Katsutoshi ^e   Ikeuchi, Takeshi ^f   Akazawa, Kohei ^g   Takami, Mako ^b,c   Hatsuta, Hiroyuki ^h   Murayama, Shigeo ^h   Hashimoto, Yasuhiro ⁱ   Miyajima, Masakazu ^j   Arai, Hajime ^j   Nagashima, Yu ^k   Yamaguchi, Haruyasu ^l   Kuwano, Ryozo ^f   Nagaike, Kazuhiro ^a   Ihara, Yasuo ^b,c,m  

^a Immuno Biological Laboratories Co Ltd   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c NEW ENERGY AND INDUSTRIAL TECHNOLOGY DEVELOPMENT ORGANIZATION   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f NIIGATA UNIVERSITY   (Japan)

^g NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^h TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

ⁱ FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^j JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l GUNMA UNIVERSITY   (Japan)

^m JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

more..

Author keywords

secretase; Amyloid protein; CSF; NSAID; Stepwise processing

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-43]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT;

EID: 84859379937     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201200214     Document Type: Article

References (30)

1. Adachi T, Saito Y, Hatsuta H, Funabe S, Tokumaru AM, Ishii K, Arai T, Sawabe M, Kanemaru K, Miyashita A, et al (2010) Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol 69: 737-744.
2. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ (2011) Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci 31: 15861-15869.
3. Hur JY, Welander H, Behbahani H, Aoki M, Frånberg J, Winblad B, Frykman S, Tjernberg LO (2008) Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J 275: 1174-1187.
4. Ishikawa M, Hashimoto M, Kuwana N, Mori E, Miyake H, Wachi A, Takeuchi T, Kazui H, Koyama H (2008) Guidelines for management of idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 48: S1-S23.
5. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of Aβ42(43) and Aβ40 in senile plaque with end-specific Aβ monoclonals: evidence that an initially deposited forms is Aβ42(43). Neuron 13: 45-53.
6. Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, Ihara Y (2006) Equimolar production of amyloid β-protein and amyloid precursor protein intracellular domain from β-carboxyl-terminal fragment by γ-secretase. J Biol Chem 281: 14776-14786.
7. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
8. Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, Asami-Odaka A, Fukushima T, Imai K, Iwatsubo T (1997) The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at Aβ42(43). Neurology 48: 741-745.
9. Kuwano R, Miyashita A, Arai H, Asada T, Imagawa M, Shoji M, Higuchi S, Urakami K, Kakita A, Takahashi H, et al (2006) Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. Hum Mol Genet 15: 2170-2182.
10. Li G, Aryan M, Silverman JM, Haroutunian V, Perl DP, Birstein S, Lantz M, Marin DB, Mohs RC, Davis KL (1997) The validity of the family history method for identifying Alzheimer disease. Arch Neurol 54: 634-640.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
12. Nakaya Y, Yamane T, Shiraishi H, Wang HQ, Matsubara E, Sato T, Dolios G, Wang R, De Strooper B, Shoji M, et al (2005) Random mutagenesis of presenilin-1 identifies novel mutants exclusively generating long amyloid β-peptides. J Biol Chem 280: 19070-19077.
13. Oshima N, Morishima-Kawashima M, Yamaguchi H, Yoshimura M, Sugihara S, Khan K, Games D, Schenk D, Ihara Y (2001) Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain. Am J Pathol 158: 2209-2218.
14. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saiso TC, Wang R, et al (2005) Longer forms of amyloid β protein: implications for the mechanism of intramembrane cleavage by γ-secretase. J Neurosci 25: 436-445.
15. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, et al (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71: 85-92.
16. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, et al (2011) Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci 14: 1023-1032.
17. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease in increase in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870.
18. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD (2005) Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same. Ann Neurol 58: 139-142.
19. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.
20. Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul S, Schafer MK, Berezovska O, et al (2009) γ-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324: 639-642.
21. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, et al (1998) Combination assay of CSF tau, Aβ1-40 and Aβ 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158: 134-140.
22. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D (2003) Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2: 506-511.
23. Simonsen AH, Hansson SF, Ruetschi U, McGuire J, Podust VN, Davies HA, Mehta P, Waldemar G, Zetterberg H, Andreasen N, et al (2007) Amyloid β1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 23: 246-250.
24. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment. J Neurosci 29: 13042-13052.
25. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T (2003) The role of presenilin cofactors in the γ-secretase complex. Nature 422: 438-441.
26. Wada S, Morishima-Kawashima M, Qi Y, Misonou H, Shimada Y, Ohno-Iwashita Y, Ihara Y (2003) Gamma-secretase activity is present in rafts but is not cholesterol-dependent. Biochemistry 47: 13977-13986.
27. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414: 212-216.
28. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, et al (2004) Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240-246.
29. Yang DS, Tandon A, Chen F, Yu G, Yu H, Arakawa S, Hasegawa H, Duthie M, Schmidt SD, Ramabhadran TV, et al (2002) Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 277: 28135-28142.
30. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, et al (2007) Angiotensin-converting enzyme converts amyloid β-protein 1-42 (Aβ(1-42)) to Aβ(1-40), and its inhibition enhances brain Aβ deposition. J Neurosci 27: 8628-8635.